Effect of pre-treatment of EGFR-TKIs on immune checkpoint inhibitor-associated interstitial lung disease in lung cancer patients: Analysis using a Japanese claims database

CONCLUSION: Although further analyses are required to confirm our findings, this study indicated that pre-treatment with EGFR-TKI might not increase the ILD risk after ICI treatment.PMID:37969096 | DOI:10.5414/CP204491

Source: International Journal of Clinical Pharmacology and Therapeutics - November 16, 2023 Category: Drugs & Pharmacology Authors: Naoto Okada Hirofumi Hamano Kenta Yagi Takahiro Niimura Fuka Aizawa Mitsuhiro Goda Yoshito Zamami Takashi Kitahara Keisuke Ishizawa Source Type: research